7 research outputs found
Expenditure on Heart Failure in the United States: The Medical Expenditure Panel Survey 2009-2018.
Automated Pupillometry as an Adjunct to Clinical Examination in Patients With Acute Vision Loss
Cancer therapy's impact on lipid metabolism: Mechanisms and future avenues.
Atherosclerotic cardiovascular disease is a growing threat among cancer patients. Not surprisingly, cancer-targeting therapies have been linked to metabolic dysregulation including changes in local and systemic lipid metabolism. Thus, tumor development and cancer therapeutics are intimately linked to cholesterol metabolism and may be a driver of increased cardiovascular morbidity and mortality in this population. Chemotherapeutic agents affect lipid metabolism through diverse mechanisms. In this review, we highlight the mechanistic and clinical evidence linking commonly used cytotoxic therapies with cholesterol metabolism and potential opportunities to limit atherosclerotic risk in this patient population. Better understanding of the link between atherosclerosis, cancer therapy, and cholesterol metabolism may inform optimal lipid therapy for cancer patients and mitigate cardiovascular disease burden
Recommended from our members
Expenditure on Heart Failure in the United States: The Medical Expenditure Panel Survey 2009-2018.
BackgroundWith rising United States health care expenditure, estimating current spending for patients with heart failure (HF) informs the value of preventative health interventions.ObjectivesThe purpose of this study was to estimate current health care expenditure growth for patients with HF in the United States.MethodsThe authors pooled MEPS (Medical Expenditure Panel Survey) data from 2009-2018 to calculate total HF-related expenditure across clinical settings in the United States. A 2-part model adjusted for demographics, comorbidities, and year was used to estimate annual mean and incremental expenditures associated with HF.ResultsIn the United States, an average of 5,727 for individuals without HF. After adjusting for demographics and comorbidities, a diagnosis of HF was associated with 26,864 annual per person in 2009-2010 to 12,569 per year. Outpatient office-based care and prescription medications saw the greatest growth in cost over the period, 41% and 24%, respectively. Estimated incremental national expenditure for HF per year was 179.5 billion.ConclusionsHF is a costly condition for which expenditure is growing faster than that of other chronic conditions
Intracardiac Aspergilloma in a Post-Transplant Patient: A Multimodal Approach to Diagnosis.
Cardiac aspergillomas are rare and associated with high mortality. We present a case of right ventricular cardiac aspergilloma in an asymptomatic renal transplant recipient. Intracavitary aspergilloma is an important consideration in evaluation of an intracardiac mass in an immunocompromised patient. (Level of Difficulty: Advanced.)